Meyer ASP, Ostrowski SR, Kjærgaard J, et al. - To test the safety of Iloprost (a prostacyclin analogue) in this predefined sub-study of the Endothelial Dysfunction in Resuscitated Cardiac Arrest (ENDO-RCA) trial, researchers assessed the alteration in whole blood platelet aggregometry (Multiplate) in out of hospital cardiac arrest (OHCA) patients from baseline to 96-h after randomization. The patients were assigned 1:2 to 48 h Iloprost infusion, (1 ng/kg/min) or placebo (saline infusion). According to the findings, platelet aggregation was not altered by the iloprost infusion, as assessed by the ASPI (arachidonic acid), TRAP (thrombin-receptor activating peptide), RISTO (Ristocetin) and (adenosin diphosphat) assays. No increased risk of bleeding or transfusion therapy was documented. For the ASPI and ADP assays, a reduction in platelet aggregation was noted during the initial 96 h post-OHCA.